The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Identifieur interne : 003171 ( Main/Merge ); précédent : 003170; suivant : 003172The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Auteurs : Anthony H. V. Schapira [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , toxicity : Antiparkinson Agents, Levodopa.
- drug effects : Blood-Brain Barrier.
- drug therapy : Parkinson Disease.
- physiology : Blood-Brain Barrier.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.
Abstract
Levodopa is the ‘gold standard’ drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22146
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002993
- to stream Istex, to step Curation: 002993
- to stream Istex, to step Checkpoint: 001149
- to stream PubMed, to step Corpus: 002052
- to stream PubMed, to step Curation: 002052
- to stream PubMed, to step Checkpoint: 002048
- to stream Ncbi, to step Merge: 002311
- to stream Ncbi, to step Curation: 002311
- to stream Ncbi, to step Checkpoint: 002311
Links to Exploration step
ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22146</idno><idno type="url">https://api.istex.fr/document/1E041800F6524CC2074E7F38AFFF9C8CE6212405/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002993</idno><idno type="wicri:Area/Istex/Curation">002993</idno><idno type="wicri:Area/Istex/Checkpoint">001149</idno><idno type="wicri:doubleKey">0885-3185:2008:Schapira A:the:clinical:relevance</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18781678</idno><idno type="wicri:Area/PubMed/Corpus">002052</idno><idno type="wicri:Area/PubMed/Curation">002052</idno><idno type="wicri:Area/PubMed/Checkpoint">002048</idno><idno type="wicri:Area/Ncbi/Merge">002311</idno><idno type="wicri:Area/Ncbi/Curation">002311</idno><idno type="wicri:Area/Ncbi/Checkpoint">002311</idno><idno type="wicri:Area/Main/Merge">003171</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S515">S515</biblScope><biblScope unit="page" to="S520">S520</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><idno type="DOI">10.1002/mds.22146</idno><idno type="ArticleID">MDS22146</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Blood-Brain Barrier (drug effects)</term><term>Blood-Brain Barrier (physiology)</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term><term>Levodopa (toxicity)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>dyskinesias</term><term>levodopa</term><term>neuroprotection</term><term>toxicity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the ‘gold standard’ drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. © 2008 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.22146"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22146</idno><idno type="url">https://api.istex.fr/document/1E041800F6524CC2074E7F38AFFF9C8CE6212405/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002993</idno><idno type="wicri:Area/Istex/Curation">002993</idno><idno type="wicri:Area/Istex/Checkpoint">001149</idno><idno type="wicri:doubleKey">0885-3185:2008:Schapira A:the:clinical:relevance</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S515">S515</biblScope><biblScope unit="page" to="S520">S520</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><idno type="DOI">10.1002/mds.22146</idno><idno type="ArticleID">MDS22146</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesias</term><term>levodopa</term><term>neuroprotection</term><term>toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the ‘gold standard’ drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. © 2008 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.22146</idno><idno type="RBID">pubmed:18781678</idno><idno type="pmid">18781678</idno><idno type="wicri:Area/PubMed/Corpus">002052</idno><idno type="wicri:Area/PubMed/Curation">002052</idno><idno type="wicri:Area/PubMed/Checkpoint">002048</idno><idno type="wicri:Area/Ncbi/Merge">002311</idno><idno type="wicri:Area/Ncbi/Curation">002311</idno><idno type="wicri:Area/Ncbi/Checkpoint">002311</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Blood-Brain Barrier (drug effects)</term><term>Blood-Brain Barrier (physiology)</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term><term>Levodopa (toxicity)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003171 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003171 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405
|texte= The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |